EFFECT OF SMOKING ON MUCUS HYPERSECRETION MECHANISMS IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Asthma and COPD are characterized by an accelerated decline in lung function associated with incompletely reversible airflow obstruction. This could be the result of lung structural changes and inflammation. Tissue repairing mechanisms may result in a restitution ad integrum of bronchial epithelium. But in most cases, especially in COPD and severe asthma, the "remodeling" is characterized by mucus cells hyperplasia, overproduction of mucus, and physicochemical, biological and immunological changes. Clinically, this mucus overproduction is reported by patients as the clinical symptom called "chronic bronchitis". Generally, it develops at a bronchiolar level where it is responsible for the progression of these diseases. There is a paradox, because the intrinsic properties of mucus seem rather beneficial so fighting against it may not be really wise at long-term. Especially its defensive effect against microbial agents which remains poorly explained. Currently, no treatment aims to reduce the production of mucus and mechanisms leading to such an overproduction are poorly understood in severe asthma and COPD. The identification of new targets to treat this overproduction of mucus in COPD is therefore of major interest.

In view of current knowledge, inflammatory mediators and signal transduction leading to increased mucin production and increased number of goblet cells are probably IL-9, IL-13, IL -1ß and TNF-α involving calcium-sensitive chloride channels. Intracellular signaling pathways seem to be based on STAT-6, FOXA2, SPDEF, EGFR and / or COX-2

Study Overview

• Status: Completed
• Conditions: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
• Intervention / Treatment: Procedure: bronchial biopsies; Other: Determination of CO in exhaled air

• Study Type: Interventional
• Enrollment (Actual): 55
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Marseille, France, 13354
    • Assistance Publique Hôpitaux de Marseille

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The patient must be given free and informed consent and signed the consent
• The patient must be a member or beneficiary of a health insurance plan
• Women and men are included (s)
• The patient is aged at least 18 years

Exclusion Criteria:

• neoplastic disease extent
• Other progressive lung disease (tuberculosis, diseases of the pulmonary interstitium, active or recent pulmonary infection.)
• Patient unstable or had experienced exacerbation in the previous month study.
• Unable to understand the nature and purpose of the study
• Not affiliated to the French social security
• Making their military or military service career
• During periods of exclusion on another protocol
• Patients who are mentally or legally can not give consent.
• Patients with recent psychiatric disorders (less than a year).
• The illicit drugs or alcohol.
• Pregnant women, nursing mothers and women in labor;
• Women of childbearing potential without effective contraception (specified in the protocol)
• Persons deprived of their liberty by a judicial or administrative decision, hospitalized without consent and persons admitted to a health or social establishment for purposes other than research;
• Minors;
• The adults subject to a measure of legal protection or unable to consent;
• The people in emergency situations can not give consent.
• People with a cons-indication for bronchial biopsies (coagulation disorders, anticoagulation can be suspended ...)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: smoking COPD	Procedure: bronchial biopsies; Other: Determination of CO in exhaled air
Experimental: smoking without COPD	Procedure: bronchial biopsies; Other: Determination of CO in exhaled air
Other: No Smoking Control	Procedure: bronchial biopsies; Other: Determination of CO in exhaled air
Experimental: severe asthma	Procedure: bronchial biopsies; Other: Determination of CO in exhaled air

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
measure the impact of cigarette smoke on the formation and composition of mucus produced by the bronchial epithelium	(physicochemical properties, protein composition and potentially beneficial role in innate immunity)	4 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
measure the concentration of intracellular calcium	induced by cigarette smoke measured by confocal microscopy using a fluorochrome (Fura-2)	4 years

Collaborators and Investigators

• Sponsor: Assistance Publique Hopitaux De Marseille
• Investigators: Study Director: LOIC MONDOLONI, Assistance Publique Hôpitaux de Marseille

Study record dates

Study Major Dates

• Study Start (Actual): June 30, 2014
• Primary Completion (Actual): December 19, 2018
• Study Completion (Actual): August 7, 2023

Study Registration Dates

• First Submitted: August 1, 2013
• First Submitted That Met QC Criteria: September 17, 2013
• First Posted (Estimated): September 20, 2013

Study Record Updates

• Last Update Posted (Actual): August 14, 2023
• Last Update Submitted That Met QC Criteria: August 7, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Disease Attributes; Chronic Disease; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: 2013-A00553-42; 2013-14 (Other Identifier: AP HM)